Apellis Pharmaceuticals



For Additional Information about APL-2 visit http://www.apellis.com  

APL-2  Study to Assess the Safety, Tolerability, efficacy and PK of APL-2 in patients with wAIHA or CAD. Phase 2 Trial ClinicalTrials.gov Identifier: NCT03226678 (Plaudit Study)

Active, Not Recruiting Last Updated Post February 7, 2020  Estimated Study Completion Date December 2020


Certain links within this site connect to other websites maintained by third parties over whom CADF has no control. CADF makes no representations as to the accuracy or any other aspect of information contained in other websites.

Providing these links does not imply any endorsement, non-endorsement, support or commercial gain by CADF.